CHARM Therapeutics

Protein-ligand intelligence to deliver next-generation small molecule therapeutics

London, United Kingdom · Founded 2021 · $130.0M raised

Headquarters
London
Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$130.0M
Last Round
$80.0M Series BSep 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Charm Therapeutics is an AI-driven drug discovery company using deep learning to design highly potent small molecule medicines. Founded by leaders with a track record in AI and drug discovery, the company applies its proprietary protein-ligand interaction platform to engineer structurally optimized inhibitors. Charm's lead program focuses on next-generation menin inhibitors for Acute Myeloid Leukemia (AML) — designed to overcome treatment resistance observed in first-generation therapies by reprogramming leukemic cells rather than simply killing them. Headquartered in London with a research presence at the Babraham Research Campus in Cambridge, Charm is advancing its pipeline toward clinical-stage validation.

Summary

CHARM Therapeutics is a Life Sciences company based in London, United Kingdom, founded in 2021. It has raised $130.0M in total across 2 rounds, most recently a $80.0M Series B round in Sep 2025.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BSep 2025
$80.0M

Sign up to see all 2 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Similar Companies

OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Chai Discovery

Chai Discovery builds frontier AI to predict and reprogram interactions between biochemical molec...

San Francisco, United States11–50Artificial Intelligence, Biotech
Series CTotal funding$630.0MJul 2026
Isomorphic Labs

AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...

London, United Kingdom201–500Artificial Intelligence, Biotech
Series BTotal funding$2.6BMay 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

CHARM Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/charm-therapeutics"><img src="https://indexed.vc/api/badge/company/charm-therapeutics" alt="CHARM Therapeutics on Indexed.vc" width="260" height="76" /></a>